ADRB2 and asthma: Optimisation and replication of the screen ultimately identified four drugs that significantly reduced SNCA mRNA and protein levels in a dose-dependent manner: three β2-adrenoceptor (β2AR) agonists, including the common asthma medication salbutamol, and riluzole, a drug licensed in amyotrophic lateral sclerosis.